beam therapeutics宣佈Beam-302在Alpha-1抗胰蛋白酶缺陷（Aa

快訊 · 06/26 18:30

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of Beam-302 in Alpha-1 Antitrypsin Deficiency (Aatd)

beam therapeutics宣佈Beam-302在Alpha-1抗胰蛋白酶缺陷（Aatd）臨床1/2期研究中已完成首例患者治療。